2024-01 – Q4 2023 Reporting

  • After an initial increasing in screening and randomization activities of patients to the SER150 CL-009 study in New Zealand this has slowed down.
  • Recruitment of patients in Australia remains very slow.
  • Private Placement of 1,3 mil B-shares was completed and the proceeds of app. NOK 17 received. It was furthermore decided to do a Subsequent Offering of B-shares in early 2024.

Read more here